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INTRODUCTION 63
Visceral leishmaniasis (VL) is an infectious parasitic disease transmitted by 64 Lutzomyia longipalpis, with Leishmania infantum chagasi being the main causative Inclusion criteria 120 The retrospective study included patients with records of VL irrespective of 121 HIV co-infection, containing complete epidemiological, clinical, and laboratory data. 122 Meanwhile, the prospective study included patients with positive serology for HIV and 123 a parasitological diagnosis of VL who were receiving treatment for co-infection at the 124 reference hospital. Meanwhile, the VL group consisted of patients with a parasitological 125 diagnosis of VL and negative serology for HIV who were treated at the reference 126 hospital. All patients included in the prospective study provided written informed 127 consent for participation. 7 Another method used enzyme-linked immunosorbent assay (ELISA), which has 137 sensitivity of 90-100% [18] . 138 HIV 139 HIV was diagnosed using ELISA and the HIV rapid test, which are routinely 140 performed at the reference state hospital following recommendations from the Health 141 Ministry. Other laboratory data used as reference were obtained using the automated were fever (p < 0.001) and hair loss (p = 0.007). The physical examination data revealed 177 that weight loss (p = 0.003), fever (p < 0001), jaundice (p < 0.001), hepatomegaly (p = 178 0.029), and splenomegaly (p = 0.007) were more frequent in the VL group. In contrast, 179 dyspnea was detected only in the VL/HIV group (p = 0.013). The frequency of 180 skin/mucosal pallor was high in both groups (p = 0.920). Table 3 shows the comparative analysis of the serum profiles between groups The distribution of variables related to treatment is shown in in which no VL case had been previously reported [26] . By observing the 244 internalization of VL, it is possible to perceive the juxtaposition that occurs between 245 these VL infections found in people living with HIV an adequate environment to 246 develop [27] .
247
In line with our findings, Cota et al. described fever and hepatosplenomegaly 248 as the most frequent complications in patients with VL alone. In contrast, Hurissa et al. 249 found typical VL complications in both studied groups [24, 25] . In their study, fever was 250 observed more frequently in patients with VL than those with VL/HIV co-infection, [23, 28] . Different 254 from many Brazilian studies, which reported the presence of splenomegaly followed by 255 fever, weight loss, and asthenia, in 81 patients with VL/HIV co-infection in Ceará [29] 256 and another study that identified weight loss, weakness, fever, and hepatosplenomegaly 257 as the most common physical changes in 65 patients with VL/HIV co-infection [13] , the 258 most common symptoms in this study were skin pallor, hepatomegaly, and levels observed in some patients with VL/HIV co-infection [33, 34, 35] was also found in 279 the present study. However, we should note that such an increase was higher in patients 280 with VL alone, as additionally reported by De Souza et al. and Cota et al. [25, 36] .
281
CD4 T-lymphocytes were quantified by several authors who emphasized, 282 similar to our study, the presence of immunosuppression with counts lower than 200 283 cells/mm 3 [25, 41] .
314
This study had several limitations. Because of the use of secondary data, 315 mainly in the retrospective study, incomplete data were obtained in some examinations.
316
Another limitation was difficulty in analyzing some laboratory data, which precluded 317 comparative analyses between the two groups, although we observed that the co- In summary, our study found that VL is a public health issue in northeastern 328 Brazil, especially in Maranhão, where its incidence is increasing. The severity of the 329 disease is greater due to co-infection with HIV, which modifies the epidemiology and 330 clinical presentation of VL. Thus, the classical triad of fever, paleness, and 331 hepatosplenomegaly was not expected. We also concluded that treatment remains 332 challenging, despite advances in antiretroviral treatment, so a definitive response to 333 treatment for VL cannot be predicted when the disease is associated with HIV. 
